This, on one hand, explains the higher sensitivity of TNBC cells to CAP treatment than non-TNBC cells and, on the other hand, suggests the possibility of using EGFR in diagnosing the sensitivity of breast cancer patients to CAP treatment. This evidence concerns the gene EGFR and breast carcinoma.